Mohammed Solayman Hossain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammed Solayman Hossain has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ho-Yeon Song
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea
9 shared publications - Sarower Hossen Shuvo
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea
8 shared publications Hoonhee Seo
K‐Microbiome Institute Asan Chungnam Republic of Korea
6 shared publicationsSukyung Kim
K‐Microbiome Institute Asan Chungnam Republic of Korea
6 shared publicationsAbdur Rahim
Human Microbiome Medical Research Center, School of Medicine, Soonchunhyang University, Asan 31538, Republic of Korea
5 shared publicationsIndrajeet Barman
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (5) , e70410
A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout
Gout is a common inflammatory disease closely associated with hyperuricemia, and its global prevalence is increasing, highlighting the need for safer and more effective therapeutic strategies. Recently, microbiome‐based therapeutics have emerged as promising alternatives, and the development of functionally validated NGP and their advanced forms, post–NGP strains, is gaining increasing attention. In this study, microbiome‐derived bacterial strains were screened based on their in vitro uric acid (UA)‐reducing capacity and hypoxanthine utilization. Among the tested strains, Mitsuokella jalaludinii exhibited the most pronounced uric acid reduction and growth enhancement in response to purine substrates compared to conventional lactic acid bacteria. This strain reduced uric acid levels by approximately 30% after 48 h ( p < 0.001) and showed significantly increased growth in purine‐enriched minimal medium ( p < 0.01). WGS further confirmed its strain‐level novelty, leading to its designation as PMC73, and revealed the presence of genetic features associated with purine metabolism and UA regulation. In a MSU‐induced RAW 264.7 macrophage model, PMC73 significantly reduced UA levels ( p < 0.001) and modulated immune responses by increasing anti‐inflammatory cytokines while decreasing pro‐inflammatory cytokines. These effects were associated with suppression of the NLRP3–caspase‐1, along with downregulation of URAT1 and XOD, indicating coordinated regulation of uric acid production, reabsorption, and inflammatory pathways. Based on safety evaluation, including d ‐lactate production, cytotoxicity assays and oral toxicity assessment in a mouse model, demonstrated that PMC73 exhibited no pathogenic or toxic properties. Therefore, PMC73 represents a promising microbiome‐based candidate with relevance to gout‐associated hyperuricemia, warranting further in vivo and clinical investigations.
- 15 September 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (5) , e70410
Open AccessA Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout
Gout is a common inflammatory disease closely associated with hyperuricemia, and its global prevalence is increasing, highlighting the need for safer and more effective therapeutic strategies. Recently, microbiome‐based therapeutics have emerged as promising alternatives, and the development of functionally validated NGP and their advanced forms, post–NGP strains, is gaining increasing attention. In this study, microbiome‐derived bacterial strains were screened based on their in vitro uric acid (UA)‐reducing capacity and hypoxanthine utilization. Among the tested strains, Mitsuokella jalaludinii exhibited the most pronounced uric acid reduction and growth enhancement in response to purine substrates compared to conventional lactic acid bacteria. This strain reduced uric acid levels by approximately 30% after 48 h ( p < 0.001) and showed significantly increased growth in purine‐enriched minimal medium ( p < 0.01). WGS further confirmed its strain‐level novelty, leading to its designation as PMC73, and revealed the presence of genetic features associated with purine metabolism and UA regulation. In a MSU‐induced RAW 264.7 macrophage model, PMC73 significantly reduced UA levels ( p < 0.001) and modulated immune responses by increasing anti‐inflammatory cytokines while decreasing pro‐inflammatory cytokines. These effects were associated with suppression of the NLRP3–caspase‐1, along with downregulation of URAT1 and XOD, indicating coordinated regulation of uric acid production, reabsorption, and inflammatory pathways. Based on safety evaluation, including d ‐lactate production, cytotoxicity assays and oral toxicity assessment in a mouse model, demonstrated that PMC73 exhibited no pathogenic or toxic properties. Therefore, PMC73 represents a promising microbiome‐based candidate with relevance to gout‐associated hyperuricemia, warranting further in vivo and clinical investigations.
- Open Access
- 12 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1603
Flavonifractor plautii as a Next-Generation Probiotic Enhancing the NGP F/P Index in a Simulated Human Gut Microbiome Ecosystem
Background/Objectives: Traditionally consumed fermented foods and lactic acid bacteria (LAB)-based products have primarily been investigated for their nutritional and health-promoting benefits as dietary supplements. More recently, research has advanced toward exploring their therapeutic potential in pharmaceutical development. However, reliance on conventional LAB strains despite their established safety and efficacy has led to saturation at the strain level, underscoring the need for next-generation probiotics (NGPs) with novel therapeutic potential. In this context, we identified Flavonifractor plautii from human feces as a candidate NGP and investigated its effects on the human gut microbiota. Methods: Whole-genome sequencing revealed distinct genetic features that supported its uniqueness, and the strain was designated PMC93. A human gut microbial ecosystem simulator was used to administer F. plautii daily for one week, after which microbial community changes were evaluated using 16S rRNA gene-based metagenomic sequencing. Results: The administration did not induce significant changes in alpha or beta diversity, suggesting that F. plautii does not disrupt overall bacterial community structure, thereby supporting its microbial community safety. Taxonomic analysis demonstrated a significant increase in the Firmicutes-to-Proteobacteria ratio (NGP F/P index). The improvement surpassed that of conventional LAB treatments and was consistently maintained under supplementation with commonly encountered pharmaceutical compounds and nutrients. The shift was associated with an increase in short-chain fatty acid (SCFA)-producing beneficial taxa and a decrease in pro-inflammatory and potentially pathogenic groups. Functional outcomes, including elevated SCFA levels and downregulation of inflammation-related gene expression, further corroborated these compositional changes. The strain also demonstrated safety in in vivo models. Conclusions: Collectively, these findings suggest that strain PMC93 is a promising NGP candidate with substantial therapeutic potential for microbiota-associated health and disease modulation, particularly due to its ability to enhance the NGP F/P index.
- 12 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1603
Open AccessFlavonifractor plautii as a Next-Generation Probiotic Enhancing the NGP F/P Index in a Simulated Human Gut Microbiome Ecosystem
Background/Objectives: Traditionally consumed fermented foods and lactic acid bacteria (LAB)-based products have primarily been investigated for their nutritional and health-promoting benefits as dietary supplements. More recently, research has advanced toward exploring their therapeutic potential in pharmaceutical development. However, reliance on conventional LAB strains despite their established safety and efficacy has led to saturation at the strain level, underscoring the need for next-generation probiotics (NGPs) with novel therapeutic potential. In this context, we identified Flavonifractor plautii from human feces as a candidate NGP and investigated its effects on the human gut microbiota. Methods: Whole-genome sequencing revealed distinct genetic features that supported its uniqueness, and the strain was designated PMC93. A human gut microbial ecosystem simulator was used to administer F. plautii daily for one week, after which microbial community changes were evaluated using 16S rRNA gene-based metagenomic sequencing. Results: The administration did not induce significant changes in alpha or beta diversity, suggesting that F. plautii does not disrupt overall bacterial community structure, thereby supporting its microbial community safety. Taxonomic analysis demonstrated a significant increase in the Firmicutes-to-Proteobacteria ratio (NGP F/P index). The improvement surpassed that of conventional LAB treatments and was consistently maintained under supplementation with commonly encountered pharmaceutical compounds and nutrients. The shift was associated with an increase in short-chain fatty acid (SCFA)-producing beneficial taxa and a decrease in pro-inflammatory and potentially pathogenic groups. Functional outcomes, including elevated SCFA levels and downregulation of inflammation-related gene expression, further corroborated these compositional changes. The strain also demonstrated safety in in vivo models. Conclusions: Collectively, these findings suggest that strain PMC93 is a promising NGP candidate with substantial therapeutic potential for microbiota-associated health and disease modulation, particularly due to its ability to enhance the NGP F/P index.
- Open Access
- 31 May 2025
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 63 (5) , e2501002
Microbiome therapeutic PMC72 through reverse translational research in gout
Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals. Urate-lowering therapies for gout have limitations, including side effects and limited efficacy, highlighting the need for novel therapeutic approaches to improve patient outcomes. In this context, our research team conducted a microbiome analysis of fecal samples from healthy individuals and gout patients, identifying Bifidobacterium as a key biomarker. Subsequently, we isolated and identified this strain, B. longum PMC72, and demonstrated its efficacy in a gout mouse model. In potassium oxonate (PO)-induced hyperuricemia mice, PMC72 significantly alleviated nausea, gait disturbances, ankle inflammation, and improved renal health. These effects were associated with marked reductions in oxidative stress markers, including serum uric acid, blood urea nitrogen, hepatic xanthine oxidase, and malondialdehyde (MDA) levels in serum, liver, and joint samples, as well as the downregulation of inflammation and uric acid transport-related gene expression in kidney samples. These benefits were comparable to those treated with Febuxostat, a standard urate-lowering therapy for gout. Furthermore, gut microbiome analysis revealed that PMC72 restored dysbiosis induced by hyperuricemia, contrasting with the reduced microbial diversity observed with febuxostat alone, and showed a complete recovery to eubiosis when combined with Febuxostat. These findings position PMC72 as a promising microbial therapeutic candidate for gout management, demonstrating significant development potential and serving as a benchmark for reverse translational microbiome-based therapeutic research.
- 31 May 2025
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 63 (5) , e2501002
Open AccessMicrobiome therapeutic PMC72 through reverse translational research in gout
Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals. Urate-lowering therapies for gout have limitations, including side effects and limited efficacy, highlighting the need for novel therapeutic approaches to improve patient outcomes. In this context, our research team conducted a microbiome analysis of fecal samples from healthy individuals and gout patients, identifying Bifidobacterium as a key biomarker. Subsequently, we isolated and identified this strain, B. longum PMC72, and demonstrated its efficacy in a gout mouse model. In potassium oxonate (PO)-induced hyperuricemia mice, PMC72 significantly alleviated nausea, gait disturbances, ankle inflammation, and improved renal health. These effects were associated with marked reductions in oxidative stress markers, including serum uric acid, blood urea nitrogen, hepatic xanthine oxidase, and malondialdehyde (MDA) levels in serum, liver, and joint samples, as well as the downregulation of inflammation and uric acid transport-related gene expression in kidney samples. These benefits were comparable to those treated with Febuxostat, a standard urate-lowering therapy for gout. Furthermore, gut microbiome analysis revealed that PMC72 restored dysbiosis induced by hyperuricemia, contrasting with the reduced microbial diversity observed with febuxostat alone, and showed a complete recovery to eubiosis when combined with Febuxostat. These findings position PMC72 as a promising microbial therapeutic candidate for gout management, demonstrating significant development potential and serving as a benchmark for reverse translational microbiome-based therapeutic research.
- Open Access
- 30 April 2025
- Published by Korean Association of Urogenital Tract Infection and Inflammation in Urogenital Tract Infection
- Vol. 20 (1) , 4-16
Emerging Insights Into Microbiome Therapeutics for Urinary Tract Infections: A Narrative Review
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, affecting millions annually and posing a significant global health concern. Traditional therapies for UTIs are becoming increasingly ineffective due to rising drug resistance and their tendency to disrupt the host's healthy microbiota, leading to further side effects. Consequently, there is an urgent need to develop alternative therapeutic agents that differ from conventional regimens and have fewer or no side effects. In this context, microbiome therapeutics offer a promising solution, given their demonstrated efficacy against various infectious diseases. Advances in scientific technology, particularly next-generation sequencing, have deepened our understanding of urinary microbiome dynamics, revealing a complex interplay within the urobiome that influences the onset and progression of UTIs. Uropathogenic bacteria do not solely cause UTIs; shifts in the composition of the urinary microbiome and interactions within the microbial community, known as host-microbiota interactions, also play a significant role. Although recent studies underscore the potential of targeting the urinary microbiome to manage UTIs and related complications, this field is still emerging and faces numerous regulatory and technical challenges. Further in-depth and comprehensive research is required to advance this pioneering concept into clinical practice.
- 30 April 2025
- Published by Korean Association of Urogenital Tract Infection and Inflammation in Urogenital Tract Infection
- Vol. 20 (1) , 4-16
Open AccessEmerging Insights Into Microbiome Therapeutics for Urinary Tract Infections: A Narrative Review
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, affecting millions annually and posing a significant global health concern. Traditional therapies for UTIs are becoming increasingly ineffective due to rising drug resistance and their tendency to disrupt the host's healthy microbiota, leading to further side effects. Consequently, there is an urgent need to develop alternative therapeutic agents that differ from conventional regimens and have fewer or no side effects. In this context, microbiome therapeutics offer a promising solution, given their demonstrated efficacy against various infectious diseases. Advances in scientific technology, particularly next-generation sequencing, have deepened our understanding of urinary microbiome dynamics, revealing a complex interplay within the urobiome that influences the onset and progression of UTIs. Uropathogenic bacteria do not solely cause UTIs; shifts in the composition of the urinary microbiome and interactions within the microbial community, known as host-microbiota interactions, also play a significant role. Although recent studies underscore the potential of targeting the urinary microbiome to manage UTIs and related complications, this field is still emerging and faces numerous regulatory and technical challenges. Further in-depth and comprehensive research is required to advance this pioneering concept into clinical practice.
- Open Access
Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis
Tuberculosis, primarily caused by Mycobacterium tuberculosis, is an airborne lung disease and continues to pose a significant global health threat, resulting in millions of deaths annually. The current treatment for tuberculosis involves a prolonged regimen of antibiotics, which leads to complications such as recurrence, drug resistance, reinfection, and a range of side effects. This scenario underscores the urgent need for novel therapeutic strategies to combat this lethal pathogen. Over the last two decades, microbiome therapeutics have emerged as promising next-generation drug candidates, offering advantages over traditional medications. In 2022, the Food and Drug Administration approved the first microbiome therapeutic for recurrent Clostridium infections, and extensive research is underway on microbiome treatments for various challenging diseases, including metabolic disorders and cancer. Research on microbiomes concerning tuberculosis commenced roughly a decade ago, and the scope of this research has broadened considerably over the last five years, with microbiome therapeutics now viewed as viable options for managing drug-resistant tuberculosis. Nevertheless, the understanding of their mechanisms is still in its infancy. Although autophagy has been extensively studied in other diseases, research into its role in tuberculosis is just beginning, with preliminary developments in progress. Against this backdrop, this comprehensive review begins by succinctly outlining tuberculosis’ characteristics and assessing existing treatments’ strengths and weaknesses, followed by a detailed examination of microbiome-based therapeutic approaches for drug-resistant tuberculosis. Additionally, this review focuses on establishing a basic understanding of microbiome treatments for tuberculosis, mainly through the lens of autophagy as a mechanism of action. Ultimately, this review aims to contribute to the foundational comprehension of microbiome-based therapies for tuberculosis, thereby setting the stage for the further advancement of microbiome therapeutics for drug-resistant tuberculosis.
Open AccessInsights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis
Tuberculosis, primarily caused by Mycobacterium tuberculosis, is an airborne lung disease and continues to pose a significant global health threat, resulting in millions of deaths annually. The current treatment for tuberculosis involves a prolonged regimen of antibiotics, which leads to complications such as recurrence, drug resistance, reinfection, and a range of side effects. This scenario underscores the urgent need for novel therapeutic strategies to combat this lethal pathogen. Over the last two decades, microbiome therapeutics have emerged as promising next-generation drug candidates, offering advantages over traditional medications. In 2022, the Food and Drug Administration approved the first microbiome therapeutic for recurrent Clostridium infections, and extensive research is underway on microbiome treatments for various challenging diseases, including metabolic disorders and cancer. Research on microbiomes concerning tuberculosis commenced roughly a decade ago, and the scope of this research has broadened considerably over the last five years, with microbiome therapeutics now viewed as viable options for managing drug-resistant tuberculosis. Nevertheless, the understanding of their mechanisms is still in its infancy. Although autophagy has been extensively studied in other diseases, research into its role in tuberculosis is just beginning, with preliminary developments in progress. Against this backdrop, this comprehensive review begins by succinctly outlining tuberculosis’ characteristics and assessing existing treatments’ strengths and weaknesses, followed by a detailed examination of microbiome-based therapeutic approaches for drug-resistant tuberculosis. Additionally, this review focuses on establishing a basic understanding of microbiome treatments for tuberculosis, mainly through the lens of autophagy as a mechanism of action. Ultimately, this review aims to contribute to the foundational comprehension of microbiome-based therapies for tuberculosis, thereby setting the stage for the further advancement of microbiome therapeutics for drug-resistant tuberculosis.
- Open Access
- 9 January 2025
- Published by Springer Nature in Current Microbiology
- Vol. 82 (2) , 1-20
Isolation of New Strains of Lactic Acid Bacteria from the Vaginal Microbiome of Postmenopausal Women and their Probiotic Characteristics
Lactic acid bacteria (LAB), traditionally consumed as fermented foods, are now being applied to the medical field beyond health-functional food as probiotics. Therefore, it is necessary to continuously discover and evaluate new strains with suitable probiotic characteristics, mainly focusing on safety. In this study, we isolated eight new strains from postmenopausal vaginal fluid using culturomics approaches, an emerging area of interest. Data showed that most strains possessed significant cell surface hydrophobicity (≥ 76%), auto-aggregation capacity (17 to 61%), strong adhesion activity (8 to 34%), and excellent resistance to gastric acid, bile salt, and digestive enzyme, enhancing their survival in the gastrointestinal tract. Moreover, the strains exhibited functional characteristics, including substantial antibacterial activity with a minimal inhibitory concentration (MIC) ranging from 12.5 to 50%. They also harbored bacteriocins genes, produced short-chain fatty acids (acetate and propionate), exhibited significant phagocytic activity, possessed high antioxidative properties, rapidly depleted sodium nitrite, and exhibited proteolysis and β-glucosidase activity. In addition, heat-killed LAB strains significantly reduced the gene expressions of proinflammatory cytokines such as IL-β, IL-6, and iNOS in macrophages. Safety assessment revealed no cytotoxicity in macrophage cell lines. All strains tested negative for biogenic amine or H2O2 production, displayed no gelatinase or hemolytic activity, lacked virulence genes or detrimental enzymes, and displayed antibiotic susceptibility. In summary, these newly isolated strains demonstrate excellent probiotic functionality with a strong focus on safety, making them promising candidates for future drug development in the relevant fields.
- 9 January 2025
- Published by Springer Nature in Current Microbiology
- Vol. 82 (2) , 1-20
Open AccessIsolation of New Strains of Lactic Acid Bacteria from the Vaginal Microbiome of Postmenopausal Women and their Probiotic Characteristics
Lactic acid bacteria (LAB), traditionally consumed as fermented foods, are now being applied to the medical field beyond health-functional food as probiotics. Therefore, it is necessary to continuously discover and evaluate new strains with suitable probiotic characteristics, mainly focusing on safety. In this study, we isolated eight new strains from postmenopausal vaginal fluid using culturomics approaches, an emerging area of interest. Data showed that most strains possessed significant cell surface hydrophobicity (≥ 76%), auto-aggregation capacity (17 to 61%), strong adhesion activity (8 to 34%), and excellent resistance to gastric acid, bile salt, and digestive enzyme, enhancing their survival in the gastrointestinal tract. Moreover, the strains exhibited functional characteristics, including substantial antibacterial activity with a minimal inhibitory concentration (MIC) ranging from 12.5 to 50%. They also harbored bacteriocins genes, produced short-chain fatty acids (acetate and propionate), exhibited significant phagocytic activity, possessed high antioxidative properties, rapidly depleted sodium nitrite, and exhibited proteolysis and β-glucosidase activity. In addition, heat-killed LAB strains significantly reduced the gene expressions of proinflammatory cytokines such as IL-β, IL-6, and iNOS in macrophages. Safety assessment revealed no cytotoxicity in macrophage cell lines. All strains tested negative for biogenic amine or H2O2 production, displayed no gelatinase or hemolytic activity, lacked virulence genes or detrimental enzymes, and displayed antibiotic susceptibility. In summary, these newly isolated strains demonstrate excellent probiotic functionality with a strong focus on safety, making them promising candidates for future drug development in the relevant fields.
- Open Access
- 31 December 2024
- Published by The Korean Society for Microbiology and The Korean Society of Virology in Journal of Bacteriology and Virology
- Vol. 54 (4) , 325-342
Identification of Probiotic Strains with Anti-Tuberculosis Activity and Their Characterization as Potential Therapeutic Agents
Tuberculosis (TB) remains a global health crisis, with the emergence of multidrugresistant strains necessitating the development of novel therapeutic strategies. Approximately one-fourth of the world's population, or 2 billion people, are infected with latent TB. The rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains of Mycobacterium tuberculosis (M. tb) poses a significant threat, reducing the effectiveness of conventional treatments. The limitations of current antibiotic regimens underscore the urgent need for alternative approaches. This highlights the urgent need for new anti-tuberculosis drugs. Probiotics, known for their health benefits against various infections, may offer a promising alternative in combating antibiotic-resistant TB. This study aimed to identify novel probiotic strains with anti-tuberculosis potential. Seven probiotic strains were selected by screening with the GFP-TB in vitro model. Treatment with probiotic extracts significantly reduced the TB burden inside macrophage cells analyzed by confocal microscopy, ranging from 51% to 76%. The anti-tuberculosis efficacy of these candidate strains was further evaluated using CFU and resazurin assays, where treatment with probiotics resulted in up to a 1.25 log reduction of viable TB in the CFU assay. To ensure the probiotic strains were safe for therapeutic application, comprehensive safety assessments were conducted, including evaluations of cytotoxicity, antibiotic susceptibility test, hemolysis, bile salt deconjugation, and D-lactate assay. Following the safety confirmation, we investigated the underlying mechanisms by which these probiotic strains enhance immunity and facilitate the clearance of TB within macrophage cells in vitro. This involved assessing autophagy gene expression and nitrite reduction, which are established methods for studying anti-tuberculosis effects. The results of these mechanistic studies align with the CFU and confocal microscopy findings, indicating that at least three of the probiotic strains have the potential to mitigate tuberculosis infection significantly. This research provides a foundation for further exploration of these probiotic strains as potential biotherapeutics in tuberculosis treatment. However, further studies on toxicity, mechanism of action, and efficacy in animals, followed by clinical trials, are necessary.
- 31 December 2024
- Published by The Korean Society for Microbiology and The Korean Society of Virology in Journal of Bacteriology and Virology
- Vol. 54 (4) , 325-342
Open AccessIdentification of Probiotic Strains with Anti-Tuberculosis Activity and Their Characterization as Potential Therapeutic Agents
Tuberculosis (TB) remains a global health crisis, with the emergence of multidrugresistant strains necessitating the development of novel therapeutic strategies. Approximately one-fourth of the world's population, or 2 billion people, are infected with latent TB. The rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains of Mycobacterium tuberculosis (M. tb) poses a significant threat, reducing the effectiveness of conventional treatments. The limitations of current antibiotic regimens underscore the urgent need for alternative approaches. This highlights the urgent need for new anti-tuberculosis drugs. Probiotics, known for their health benefits against various infections, may offer a promising alternative in combating antibiotic-resistant TB. This study aimed to identify novel probiotic strains with anti-tuberculosis potential. Seven probiotic strains were selected by screening with the GFP-TB in vitro model. Treatment with probiotic extracts significantly reduced the TB burden inside macrophage cells analyzed by confocal microscopy, ranging from 51% to 76%. The anti-tuberculosis efficacy of these candidate strains was further evaluated using CFU and resazurin assays, where treatment with probiotics resulted in up to a 1.25 log reduction of viable TB in the CFU assay. To ensure the probiotic strains were safe for therapeutic application, comprehensive safety assessments were conducted, including evaluations of cytotoxicity, antibiotic susceptibility test, hemolysis, bile salt deconjugation, and D-lactate assay. Following the safety confirmation, we investigated the underlying mechanisms by which these probiotic strains enhance immunity and facilitate the clearance of TB within macrophage cells in vitro. This involved assessing autophagy gene expression and nitrite reduction, which are established methods for studying anti-tuberculosis effects. The results of these mechanistic studies align with the CFU and confocal microscopy findings, indicating that at least three of the probiotic strains have the potential to mitigate tuberculosis infection significantly. This research provides a foundation for further exploration of these probiotic strains as potential biotherapeutics in tuberculosis treatment. However, further studies on toxicity, mechanism of action, and efficacy in animals, followed by clinical trials, are necessary.
- Open Access
- 11 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107274
Anti-tuberculosis effect of microbiome therapeutic PMC205 in extensively drug-resistant pulmonary tuberculosis in vivo
- 11 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107274
Open AccessAnti-tuberculosis effect of microbiome therapeutic PMC205 in extensively drug-resistant pulmonary tuberculosis in vivo
- Open Access
- 9 July 2024
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 213 (1) , 1-17
Exploring the potential of Lactocaseibacillus rhamnosus PMC203 in inducing autophagy to reduce the burden of Mycobacterium tuberculosis
Mycobacterium tuberculosis, a lethal pathogen in human history, causes millions of deaths annually, which demands the development of new concepts of drugs. Considering this fact, earlier research has explored the anti-tuberculosis potential of a probiotic strain, Lactocaseibacillus rhamnosus PMC203, leading to a subsequent focus on the molecular mechanism involved in its effect, particularly on autophagy. In this current study, immunoblotting-based assay exhibited a remarkable expression of autophagy marker LC3-II in the PMC203 treated group compared to an untreated group. A remarkable degradation of p62 was also noticed within treated cells compared to control. Furthermore, the immunofluorescence-based assay showed significant fold change in fluorescence intensity for alexa-647-LC3 and alexa-488-LC3, whereas p62 was degraded noticeably. Moreover, lysosomal biogenesis generation was elevated significantly in terms of LAMP1 and acidic vesicular organelles. As a result, PMC203-induced autophagy played a vital role in reducing M. tuberculosis burden within the macrophages in treated groups compared to untreated group. A colony -forming unit assay also revealed a significant reduction in M. tuberculosis in the treated cells over time. Additionally, the candidate strain significantly upregulated the expression of autophagy induction and lysosomal biogenesis genes. Together, these results could enrich our current knowledge of probiotics-mediated autophagy in tuberculosis and suggest its implications for innovatively managing tuberculosis.
- 9 July 2024
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 213 (1) , 1-17
Open AccessExploring the potential of Lactocaseibacillus rhamnosus PMC203 in inducing autophagy to reduce the burden of Mycobacterium tuberculosis
Mycobacterium tuberculosis, a lethal pathogen in human history, causes millions of deaths annually, which demands the development of new concepts of drugs. Considering this fact, earlier research has explored the anti-tuberculosis potential of a probiotic strain, Lactocaseibacillus rhamnosus PMC203, leading to a subsequent focus on the molecular mechanism involved in its effect, particularly on autophagy. In this current study, immunoblotting-based assay exhibited a remarkable expression of autophagy marker LC3-II in the PMC203 treated group compared to an untreated group. A remarkable degradation of p62 was also noticed within treated cells compared to control. Furthermore, the immunofluorescence-based assay showed significant fold change in fluorescence intensity for alexa-647-LC3 and alexa-488-LC3, whereas p62 was degraded noticeably. Moreover, lysosomal biogenesis generation was elevated significantly in terms of LAMP1 and acidic vesicular organelles. As a result, PMC203-induced autophagy played a vital role in reducing M. tuberculosis burden within the macrophages in treated groups compared to untreated group. A colony -forming unit assay also revealed a significant reduction in M. tuberculosis in the treated cells over time. Additionally, the candidate strain significantly upregulated the expression of autophagy induction and lysosomal biogenesis genes. Together, these results could enrich our current knowledge of probiotics-mediated autophagy in tuberculosis and suggest its implications for innovatively managing tuberculosis.